📊 CRNX Key Takeaways
Investment Thesis
Crinetics is a pre-commercial stage biopharmaceutical company with minimal revenue generation ($7.7M) against massive operating losses (-$516.8M), unsustainable cash burn (-$377.9M operating cash flow), and a cash runway that appears limited despite a strong balance sheet. The company's high liquidity and zero debt provide temporary financial stability, but negative profitability metrics across all dimensions and deteriorating net income trends signal fundamental business challenges.
CRNX Strengths
- Strong balance sheet with $1.1B in total assets and minimal leverage (0.0x debt/equity)
- Excellent liquidity position with 12.32x current ratio and $101.5M in cash equivalents
- Revenue growth of 640.7% YoY demonstrates early commercialization progress for pipeline products
CRNX Risks
- Severe cash burn of -$377.9M in operating cash flow against only $101.5M cash reserves indicates runway of ~3 months without additional funding
- Operating losses of -$516.8M with negative net margin of -6046.2% indicate pre-profitability stage with significant burn before potential product monetization
- Clinical-stage pharmaceutical model carries inherent risks of pipeline failures, regulatory delays, and competitive pressures in drug development
Key Metrics to Watch
- Quarterly cash burn rate and remaining runway before next financing event
- Clinical trial progress and FDA milestone achievements for lead candidate programs
- Revenue growth trajectory and commercialization timeline for approved or near-approval products
CRNX Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 12.32x current ratio provides a solid financial cushion.
CRNX Profitability Ratios
CRNX vs Healthcare Sector
How Crinetics Pharmaceuticals, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CRNX Balance Sheet & Liquidity
CRNX 5-Year Financial Trend
5-Year Trend Summary: Crinetics Pharmaceuticals, Inc.'s revenue has grown significantly by 217% over the 5-year period, indicating strong business expansion. The most recent EPS of $-3.69 indicates the company is currently unprofitable.
CRNX Growth Metrics (YoY)
CRNX Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$76.8M | $-0.96 |
| Q2 2025 | $399.0K | -$74.1M | $-0.94 |
| Q1 2025 | $361.0K | -$66.9M | $-0.93 |
| Q3 2024 | N/A | -$57.5M | $-0.96 |
| Q2 2024 | $399.0K | -$51.0M | $-0.94 |
| Q1 2024 | $640.0K | -$46.0M | $-0.85 |
| Q3 2023 | $346.0K | -$41.9M | $-0.78 |
| Q2 2023 | $439.0K | -$42.4M | $-0.81 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CRNX Capital Allocation
CRNX SEC Filings
Access official SEC EDGAR filings for Crinetics Pharmaceuticals, Inc. (CIK: 0001658247)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Mar 18, 2026 | 4 | xslF345X06/wk-form4_1773868401.xml | View → |
| Mar 18, 2026 | 4 | xslF345X06/wk-form4_1773868275.xml | View → |
| Mar 18, 2026 | 4 | xslF345X06/wk-form4_1773867929.xml | View → |
| Mar 13, 2026 | 4 | xslF345X05/wk-form4_1773438366.xml | View → |
| Mar 4, 2026 | 4 | xslF345X05/wk-form4_1772664285.xml | View → |
❓ Frequently Asked Questions about CRNX
What is the AI rating for CRNX?
Crinetics Pharmaceuticals, Inc. (CRNX) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CRNX's key strengths?
Strong balance sheet with $1.1B in total assets and minimal leverage (0.0x debt/equity). Excellent liquidity position with 12.32x current ratio and $101.5M in cash equivalents.
What are the risks of investing in CRNX?
Severe cash burn of -$377.9M in operating cash flow against only $101.5M cash reserves indicates runway of ~3 months without additional funding. Operating losses of -$516.8M with negative net margin of -6046.2% indicate pre-profitability stage with significant burn before potential product monetization.
What is CRNX's revenue and growth?
Crinetics Pharmaceuticals, Inc. reported revenue of $7.7M.
Does CRNX pay dividends?
Crinetics Pharmaceuticals, Inc. does not currently pay dividends.
Where can I find CRNX SEC filings?
Official SEC filings for Crinetics Pharmaceuticals, Inc. (CIK: 0001658247) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CRNX's EPS?
Crinetics Pharmaceuticals, Inc. has a diluted EPS of $-4.95.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.